118 related articles for article (PubMed ID: 35187841)
21. [Long-term outcome of childhood T-cell acute lymphoblastic leukemia treated with modified national protocol of childhood leukemia in China-acute lymphoblastic leukemia 2008].
Liao C; Shen DY; Xu XJ; Xu WQ; Zhang JY; Song H; Yang SL; Zhao FY; Shen HP; Tang YM
Zhonghua Er Ke Za Zhi; 2020 Sep; 58(9):758-763. PubMed ID: 32872717
[No Abstract] [Full Text] [Related]
22. Results of Dana-Farber Cancer Institute Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1981-1995).
Silverman LB; Declerck L; Gelber RD; Dalton VK; Asselin BL; Barr RD; Clavell LA; Hurwitz CA; Moghrabi A; Samson Y; Schorin MA; Lipton JM; Cohen HJ; Sallan SE
Leukemia; 2000 Dec; 14(12):2247-56. PubMed ID: 11187916
[TBL] [Abstract][Full Text] [Related]
23. The long-term results of childhood acute lymphoblastic leukemia at two centers from Turkey: 15 years of experience with the ALL-BFM 95 protocol.
Güneş AM; Oren H; Baytan B; Bengoa SY; Evim MS; Gözmen S; Tüfekçi O; Karapınar TH; Irken G
Ann Hematol; 2014 Oct; 93(10):1677-84. PubMed ID: 24863691
[TBL] [Abstract][Full Text] [Related]
24. Intensified therapy for infants with acute lymphoblastic leukemia: results from the Dana-Farber Cancer Institute Consortium.
Silverman LB; McLean TW; Gelber RD; Donnelly MJ; Gilliland DG; Tarbell NJ; Sallan SE
Cancer; 1997 Dec; 80(12):2285-95. PubMed ID: 9404706
[TBL] [Abstract][Full Text] [Related]
25. Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia.
Moghrabi A; Levy DE; Asselin B; Barr R; Clavell L; Hurwitz C; Samson Y; Schorin M; Dalton VK; Lipshultz SE; Neuberg DS; Gelber RD; Cohen HJ; Sallan SE; Silverman LB
Blood; 2007 Feb; 109(3):896-904. PubMed ID: 17003366
[TBL] [Abstract][Full Text] [Related]
26. [Outcome of children with T cell acute lymphoblastic leukemia treated with Chinese Children Leukemia Group acute lymphoblastic leukemia (CCLG-ALL) 2008 protocol].
Liu XM; Chen XJ; Zou Y; Wang SC; Wang M; Zhang L; Chen YM; Yang WY; Guo Y; Zhu XF
Zhonghua Er Ke Za Zhi; 2019 Oct; 57(10):761-766. PubMed ID: 31594062
[No Abstract] [Full Text] [Related]
27. Management of Ontario children with acute lymphoblastic leukemia by the Dana-Farber Cancer Institute protocols.
Desai SJ; Barr RD; Andrew M; deVeber LL; Pai MK
CMAJ; 1989 Oct; 141(7):693-7. PubMed ID: 2790605
[TBL] [Abstract][Full Text] [Related]
28. Results of treatment of lymphoblastic lymphoma at the children cancer hospital Egypt - A single center experience.
Rahman Sayed HA; Sedky M; Hamoda A; Kinaaie NE; Wakeel ME; Hesham D
J Egypt Natl Canc Inst; 2016 Sep; 28(3):175-81. PubMed ID: 27339800
[TBL] [Abstract][Full Text] [Related]
29. Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial.
Vora A; Goulden N; Mitchell C; Hancock J; Hough R; Rowntree C; Moorman AV; Wade R
Lancet Oncol; 2014 Jul; 15(8):809-18. PubMed ID: 24924991
[TBL] [Abstract][Full Text] [Related]
30. Reduced intensity of early intensification does not increase the risk of relapse in children with standard risk acute lymphoblastic leukemia - a multi-centric clinical study of GD-2008-ALL protocol.
Li XY; Li JQ; Luo XQ; Wu XD; Sun X; Xu HG; Li CG; Liu RY; Sun XF; Chen HQ; Lin YD; Li CK; Fang JP
BMC Cancer; 2021 Jan; 21(1):59. PubMed ID: 33435902
[TBL] [Abstract][Full Text] [Related]
31. Comparative results of two intensive treatment programs for childhood acute lymphoblastic leukemia: The Berlin-Frankfurt-Münster and Dana-Farber Cancer Institute protocols.
Niemeyer CM; Reiter A; Riehm H; Donnelly M; Gelber RD; Sallan SE
Ann Oncol; 1991; 2(10):745-9. PubMed ID: 1801880
[TBL] [Abstract][Full Text] [Related]
32. Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia: a prospective study.
Pui CH; Pei D; Coustan-Smith E; Jeha S; Cheng C; Bowman WP; Sandlund JT; Ribeiro RC; Rubnitz JE; Inaba H; Bhojwani D; Gruber TA; Leung WH; Downing JR; Evans WE; Relling MV; Campana D
Lancet Oncol; 2015 Apr; 16(4):465-74. PubMed ID: 25800893
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and Toxicity of Pegaspargase and Calaspargase Pegol in Childhood Acute Lymphoblastic Leukemia: Results of DFCI 11-001.
Vrooman LM; Blonquist TM; Stevenson KE; Supko JG; Hunt SK; Cronholm SM; Koch V; Kay-Green S; Athale UH; Clavell LA; Cole PD; Harris MH; Kelly KM; Laverdiere C; Leclerc JM; Michon B; Place AE; Schorin MA; Welch JJG; Neuberg DS; Sallan SE; Silverman LB
J Clin Oncol; 2021 Nov; 39(31):3496-3505. PubMed ID: 34228505
[TBL] [Abstract][Full Text] [Related]
34. Treatment of childhood acute lymphoblastic leukemia: results of Dana-Farber ALL Consortium Protocol 87-01.
LeClerc JM; Billett AL; Gelber RD; Dalton V; Tarbell N; Lipton JM; Barr R; Clavell LA; Asselin B; Hurwitz C; Schorin M; Lipshultz SE; Declerck L; Silverman LB; Cohen HJ; Sallan SE
J Clin Oncol; 2002 Jan; 20(1):237-46. PubMed ID: 11773175
[TBL] [Abstract][Full Text] [Related]
35. Minimal residual disease-guided treatment deintensification for children with acute lymphoblastic leukemia: results from the Malaysia-Singapore acute lymphoblastic leukemia 2003 study.
Yeoh AE; Ariffin H; Chai EL; Kwok CS; Chan YH; Ponnudurai K; Campana D; Tan PL; Chan MY; Kham SK; Chong LA; Tan AM; Lin HP; Quah TC
J Clin Oncol; 2012 Jul; 30(19):2384-92. PubMed ID: 22614971
[TBL] [Abstract][Full Text] [Related]
36. [Clinical and Prognostic analysis of 43 Children with Mature B-cell Non-Hodgkin's Lymphoma/Acute Lymphoblastic Leukemia].
Guo J; Zhu YP; Gao J; Li Q; Jia CS; Zhou CY; Guo X
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Feb; 24(1):72-9. PubMed ID: 26913397
[TBL] [Abstract][Full Text] [Related]
37. [Prognostic significance and risk factors of minimal residual disease ≥1% on 19th day of induction chemotherapy in children with acute lymphoblastic leukemia].
Yu J; Yi T; Lin G; Wen J; Chen L; Chen J; Wu X
Nan Fang Yi Ke Da Xue Xue Bao; 2020 Feb; 40(2):255-261. PubMed ID: 32376526
[TBL] [Abstract][Full Text] [Related]
38. Impact of Socioeconomic Status on Timing of Relapse and Overall Survival for Children Treated on Dana-Farber Cancer Institute ALL Consortium Protocols (2000-2010).
Bona K; Blonquist TM; Neuberg DS; Silverman LB; Wolfe J
Pediatr Blood Cancer; 2016 Jun; 63(6):1012-8. PubMed ID: 26913850
[TBL] [Abstract][Full Text] [Related]
39. Prognostic factors of childhood acute lymphoblastic leukemia with TCF3::PBX1 in CCCG-ALL-2015: A multicenter study.
Zhang H; Wan Y; Wang H; Cai J; Yu J; Hu S; Fang Y; Gao J; Jiang H; Yang M; Liang C; Jin R; Tian X; Ju X; Hu Q; Jiang H; Li Z; Wang N; Sun L; Leung AWK; Wu X; Qian X; Qian M; Li CK; Yang J; Tang J; Zhu X; Shen S; Zhang L; Pui CH; Zhai X
Cancer; 2023 Jun; 129(11):1691-1703. PubMed ID: 36943767
[TBL] [Abstract][Full Text] [Related]
40. [Long-term results of multicenter study based on childhood acute lymphoblastic leukemia 2005 protocol].
Cai JY; Wang NL; Jiang H; Shen SH; Xue HL; Chen J; Pan C; Gao YJ; Sun LR; Yuan XJ; Gu LJ; Tang JY
Zhonghua Er Ke Za Zhi; 2018 Jul; 56(7):511-517. PubMed ID: 29996184
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]